Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 8/20 | 0.45 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.40 |
| ▸ | AR | P10275 | 2/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.36 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.36 |
| ▸ | NSD2 | O96028 | 1/20 | 0.36 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.35 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1367657 | 0.84 | AR (0.49) | PIK3CDNOTUMARGPR119 | |
| SCHEMBL1367658 | 0.84 | AR (0.49) | PIK3CDNOTUMARGPR119 | |
| SCHEMBL1366089 | 0.83 | NOTUM (0.48) | PIK3CDNOTUMNSD2PIK3R1 | |
| SCHEMBL12143077 | 0.81 | SIRT2 (0.36) | PIK3CDGPR119SIRT2SIRT1 | |
| SCHEMBL1365674 | 0.80 | PIK3CD (0.46) | PIK3CDNOTUMARPIK3R1 | |
| SCHEMBL24989011 | 0.74 | AR (0.61) | ARGPR119 | |
| SCHEMBL22914770 | 0.74 | AR (0.61) | ARGPR119 | |
| SCHEMBL12461087 | 0.74 | PIK3CD (0.54) | PIK3CDNOTUMNSD2PIK3R1 | |
| SCHEMBL30807353 | 0.73 | GSK3B (0.51) | — | |
| SCHEMBL4444228 | 0.73 | GSK3B (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170000749-A1 | Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase | FMR LLC | 2017-01-05 | — | — | US | disclosed |
| US-20160222026-A1 | Dibenzo[B,F][1,4]oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors | FMR LLC | 2016-08-04 | — | — | US | disclosed |
| EP-2966078-A2 | Inhibitors of histone deacetylase | MethylGene Inc. (CA) | 2016-01-13 | — | — | EP | disclosed |
| US-9193749-B2 | Dibenzo[b,f][1,4]oxazepin-11-yl-N-hydroxybenzamides as HDAC inhibitors | FORUM PHARMACEUTICALS, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-20150080325-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE | ENVIVO PHARMACEUTICALS, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| US-20140011988-A1 | Dibenzo[B,F][1,4]Oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors | FMR LLC | 2014-01-09 | — | — | US | disclosed |
| US-8399452-B2 | Anticancer agents; antiproliferative agenst; antiprotozoa agents | METHYLGENE INC. (CA) | 2013-03-19 | — | — | US | disclosed |
| EP-2489657-A2 | Inhibitors of histone deacetylase | MethylGene Inc. (CA) | 2012-08-22 | — | — | EP | disclosed |
| US-20110288070-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE | FMR LLC | 2011-11-24 | — | — | US | disclosed |
| US-20110196147-A1 | INHIBITORS OF HISTONE DEACETYLASE | FMR LLC | 2011-08-11 | — | — | US | disclosed |
| EP-2343286-A1 | Dibenzo[b,f][1,4]oxazepine derivatives as inhibitors of histone deacetylase | Methylgene, Inc. (CA) | 2011-07-13 | — | — | EP | disclosed |
| US-20080207590-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288070-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC5, HDAC2 | PIK3CD 3546/4885NOTUM 1747/4885AR 3323/4885 |
| US-20080207590-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC5, HDAC11 | PIK3CD 3133/4885NOTUM 1875/4885AR 1181/4885 |
| US-20150080325-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC5, HDAC2 | PIK3CD 3546/4885NOTUM 1747/4885AR 3323/4885 |
| US-20170000749-A1 | Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase | HDAC5, KAT2A, HDAC1 | PIK3CD 3430/4885NOTUM 1916/4885AR 3238/4885 |
| US-20160222026-A1 | Dibenzo[B,F][1,4]oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors | HDAC1, HDAC2, HDAC4 | PIK3CD 1903/4885NOTUM 2202/4885AR 1063/4885 |
| US-20110196147-A1 | INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC5, HDAC11 | PIK3CD 3133/4885NOTUM 1875/4885AR 1181/4885 |
| US-20140011988-A1 | Dibenzo[B,F][1,4]Oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors | HDAC1, HDAC2, HDAC4 | PIK3CD 1903/4885NOTUM 2202/4885AR 1063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.